<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098511</url>
  </required_header>
  <id_info>
    <org_study_id>CE 16.379</org_study_id>
    <nct_id>NCT03098511</nct_id>
  </id_info>
  <brief_title>CT-Perfusion for Neurological Diagnostic Evaluation</brief_title>
  <acronym>INDex-CTP</acronym>
  <official_title>CT-Perfusion for Neurological Diagnostic Evaluation: a Prospective Canadian Multicenter Diagnostic Test Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the purpose of organ donation after neurological determination of death (NDD), death must&#xD;
      be declared using a set of standardized clinical criteria. When a full clinical evaluation&#xD;
      cannot be completed, additional neuroimaging ancillary testing is required. The ideal&#xD;
      ancillary test for NDD would demonstrate no cerebral blood flow, be free of false-positive&#xD;
      and false negative results, rapid, safe, readily available, non-invasive, and inexpensive. No&#xD;
      current ancillary test for NDD meets these criteria. Computed tomography (CT) perfusion has&#xD;
      the characteristics of an ideal test for NDD, but has not been evaluated for routine clinical&#xD;
      use for NDD.&#xD;
&#xD;
      The overarching goal of this project is to improve the NDD process by establishing&#xD;
      CT-perfusion as the ideal ancillary test. A large prospective Canadian multi-centre&#xD;
      diagnostic cohort study will be conducted to validate CT-perfusion for the neurological&#xD;
      determination of death.&#xD;
&#xD;
      Specific objectives are:&#xD;
&#xD;
      Primary objective: To determine diagnostic accuracy of CT-perfusion compared to complete&#xD;
      clinical evaluation for NDD.&#xD;
&#xD;
      Secondary objectives: 1) To confirm the safety of performing CT-perfusion in critically ill&#xD;
      patients suspected of being neurologically deceased; 2) To establish the CT-perfusion&#xD;
      inter-rater reliability for NDD; 3) To evaluate the diagnostic accuracy of CT-angiography&#xD;
      compared to complete clinical evaluation and to CT-perfusion for NDD; 4) To describe the&#xD;
      clearance of commonly used sedatives and narcotics in the setting of NDD; and 5) to&#xD;
      investigate biological changes (inflammatory and nanovesicles) that occur in humans during&#xD;
      the brain dying process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a large prospective Canadian multi-centre diagnostic cohort&#xD;
      study. The primary diagnostic test evaluated will be CT-perfusion. The reference standard&#xD;
      will be the complete clinical evaluation of brainstem functions. Comatose patients at high&#xD;
      risk of neurological death exempt of confounding factors (e.g. hypothermic patients, use of&#xD;
      long-acting sedatives, etc.) will be included. All patients will undergo CT-perfusion of the&#xD;
      head (with CT-angiography reconstructions) followed by a complete NDD assessment. Both&#xD;
      CT-perfusion and the clinical exam will be performed by independent assessors blinded from&#xD;
      each others' interpretation. The primary endpoints will be the sensitivity and specificity of&#xD;
      CT-perfusion to confirm NDD. Safety endpoints will be CT-perfusion -related adverse events&#xD;
      (i.e. contrast-induced kidney injury, new hemodynamic instability while undergoing&#xD;
      CT-perfusion). The true negative, true positive, false negative and false positive for&#xD;
      CT-angiography obtained from the CT-perfusion source images when compared to the reference&#xD;
      standard as well as when compared to the CT-Perfusion will also be reported. The sensitivity&#xD;
      and specificity of CT-angiography compared to the reference standard and to CT-perfusion&#xD;
      along with corresponding 95% confidence intervals will be calculated. Individual patient and&#xD;
      population pharmacokinetics of analgesics and sedatives will be determined. To better&#xD;
      investigate the impact of residual circulating sedative or narcotic levels on the accuracy of&#xD;
      CT-Perfusion and CT-Angiography, Receiver Operating Characteristics (ROC) curves for varying&#xD;
      levels of narcotic or sedative thresholds and compute the ROC area under the curve for each&#xD;
      threshold will be plotted. To assess the immune phenotype, peripheral blood mononuclear cells&#xD;
      activation will be evaluated by flow cytometry and cytokines by multiplex analyses.&#xD;
      Nanovesicles fraction will be isolated from the plasma by ultracentrifugation and antigenic&#xD;
      content and enzymatic activity. The plasma will finally be analysed by ELISAs and multiplex&#xD;
      analyses to determine the levels of pro-inflammatory cytokines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participant will be comatose&#xD;
Care providers, investigators and outcome assessors will be blinded from the results of the CT-Perfusion scan result (for the clinical assessment) and from the clinical assessment results (for the CT-Perfusion scan interpretation)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of CT-perfusion</measure>
    <time_frame>CT-Perfusion scan and clinical assessment must be less than 2 hours apart</time_frame>
    <description>Sensitivity and specificity for brainstem death of CT-perfusion compared to the clinical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive Values</measure>
    <time_frame>CT-Perfusion scan and clinical assessment must be less than 2 hours apart</time_frame>
    <description>Positive and negative predictive values between two independent neuroradiology interpretations of CT-perfusion for brainstem death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likelihood Ratios</measure>
    <time_frame>CT-Perfusion scan and clinical assessment must be less than 2 hours apart</time_frame>
    <description>Positive and negative likelihood ratios between two independent neuroradiology interpretations of CT-perfusion for brainstem death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-rater Agreement</measure>
    <time_frame>CT-Perfusion scan and clinical assessment must be less than 2 hours apart</time_frame>
    <description>Between two independent neuroradiology interpretations of CT-perfusion for brainstem death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution</measure>
    <time_frame>48 hours</time_frame>
    <description>Volume of distribution from serum concentrations and drug dosing history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>48 hours</time_frame>
    <description>Volume of plasma completely cleared of the drug expressed as mL/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant</measure>
    <time_frame>48 hours</time_frame>
    <description>Rate at which the drug is removed from the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration-time Curve</measure>
    <time_frame>48 hours</time_frame>
    <description>Concentration of drug versus time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of CT-perfusion at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Sensitivity and specificity for brainstem death of CT-perfusion compared to the clinical examination for a good mRS score (3 or less) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the Predictive Values at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Positive and negative predictive values between two independent neuroradiology interpretations of CT-perfusion for brainstem death for a good mRS score (3 or less) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the Likelihood Ratios at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Positive and negative likelihood ratios between two independent neuroradiology interpretations of CT-perfusion for brainstem death for a good mRS score (3 or less) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the Inter-rater Agreement at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Between two independent neuroradiology interpretations of CT-perfusion for brainstem death for a good mRS score (3 or less) at 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">333</enrollment>
  <condition>Neurological Determination of Death</condition>
  <arm_group>
    <arm_group_label>Neurological Diagnostic Evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neurological Diagnostic Evaluation</intervention_name>
    <description>Clinical Data:&#xD;
Demographic data&#xD;
Daily data (clinical exams, laboratory data)&#xD;
Drug administration&#xD;
Additional clinical or ancillary neurological determination test&#xD;
Diagnostic Intervention:&#xD;
CT-Perfusion&#xD;
CT-Angiography reconstructions&#xD;
Reference Standard:&#xD;
- Clinical Neurological Exam&#xD;
Blood Samples (Pharmacokinetics, Inflammatory &amp; Nanovesicles Parameters):&#xD;
At the time of patient enrolment&#xD;
6 hours after patient enrolment&#xD;
At the time of the clinical neurological exam&#xD;
Secondary Outcome measures at 6 months:&#xD;
extended Glasgow Outcome Scale (GOSe)&#xD;
modified Rankin Scale (mRS)</description>
    <arm_group_label>Neurological Diagnostic Evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 years and older&#xD;
&#xD;
          2. Admitted in the intensive care unit with a brain injury&#xD;
&#xD;
          3. Glasgow Coma Scale (GCS) = 3&#xD;
&#xD;
          4. Sedation stopped for at least 6 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the following contraindications to CT-perfusion will be excluded from&#xD;
             the study:&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Contrast allergy&#xD;
&#xD;
               -  Clinician refuses inclusion because of kidney injury.&#xD;
&#xD;
          2. Patients with any of the following confounding factors precluding complete clinical&#xD;
             neurological evaluation will be excluded from the study:&#xD;
&#xD;
               -  Cervical fracture above C6&#xD;
&#xD;
               -  Significant facial trauma limiting cranial nerve examination&#xD;
&#xD;
               -  Hypothermia &lt; 34 °C&#xD;
&#xD;
               -  Use of intravenous barbiturates at any time since admission&#xD;
&#xD;
               -  Unresuscitated shock&#xD;
&#xD;
               -  Peripheral nerve or muscle dysfunction or neuromuscular blockade potentially&#xD;
                  accounting for unresponsiveness&#xD;
&#xD;
               -  Anoxic brain injury &lt; 24h (or 72h if therapeutic hypothermia)&#xD;
&#xD;
               -  Attending physician disagrees to conduct an apnea test&#xD;
&#xD;
               -  Any other abnormalities deemed a confounding factor for NDD by the attending&#xD;
                  clinician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaël Chassé, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jai JS Shankar, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaël Chassé, MD PhD FRCPC</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>30816</phone_ext>
    <email>michael.chasse.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polina Titova, BA</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>30748</phone_ext>
    <email>polina.titova.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Winnipeg Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Gibson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Noha Aref</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St-Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurological Determination of Death</keyword>
  <keyword>Determination of Death</keyword>
  <keyword>CT-Perfusion scan</keyword>
  <keyword>Ancillary Test</keyword>
  <keyword>Organ Donation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

